Post on 04-Oct-2020
New YORK CITY
October 25, 2018
MEDIA KIT 2018
/ 4 PRIX GALIEN USA FOUNDING COMMITTEE
/ 5 2018 AWARDS COMMITTEE
/ 6-7 GALIEN FORUM Overview & Background “They participated in the Forum”
/ 8-9 TESTIMONIALS FROM AROUND THE GLOBE
/ 10 HALL OF FAME - HISTORY OF THE PRIZE AND MEDAL
/ 11 PRIX GALIEN USA
/ 12 THE PRO BONO HUMANUM AWARD
/ 13 WHO WAS GALEN
/ 14 PRIX GALIEN MEDSTART UP
/ 15 PRIX GALIEN USA WINNERS
Pre-event & On-siteResources for Journalists
Galien Foundation events are conducted fully on the record, and we welcome
and invite members of the media to participate as engaged stakeholders via
onsite discussion, as well as via social media, and to report on proceedings
and outcomes.
We certainly appreciate coverage of our events, but our priority is to help you
explore and uncover today’s key issues and connect with the people and diverse
organizations we bring together that make the world a healthier place.
To help facilitate your engagement with our speakers and stakeholders,
we are delighted to work with you in the lead-up to our 2018 Forum and
Ceremony on:
Arranging interviews with key speakers
and stakeholders
Reserving private spaces for on-site interviews
Sharing our latest programs and speaker lists
Providing hi-resolutions imagery (including photos
of people, spaces, logos, etc.)
For more information and register for a press pass please contact:
Finn PartnersHolmes Report & PR News Midsize Agency of the Year
Contact:Giana GreggaT +1 312 329 3910M +1 708 703 2210 giana.gregga@finnpartners.com
Helpful linkswww.galienfoundation.org
Prix Galien USA
Forum (latest programs, participants,
registration, and reports)
Pro Bono Humanum Award
Med StartUp Award
Prix Galien Around the Globe
Prix Galien Hall of Fame
2
Sue Desmond-Hellmann, Ethiopia Clinic site visit
The Prix Galien is more than an award: it is a movement with a mandate to foster, recognize and reward excellence in scientific innovation to improve the state of human health. Building on an unrivaled network of Top biomedical scientists including Nobel Laureates in medicine, the Prix Galien manages an independent, cross-functional and geographically diverse program of events and sponsorships to brand “the best of the best” in new medicines and diagnostics.
Our scope is global, and our commitment to progress in medicine is both measurable and concrete. Our members express this through the establishment of productive relationships to build lasting bridges between the commercial research enterprise and local communities engaged in public policy, science, finance, academic research and the media.
In addition to recognizing advances in promising therapies, the Prix Galien’s annual Pro Bono Humanum Award for humanitarian achievements brings a unique focus to the intersection between science, business
and politics. The outcome we seek is guided by the synthesis principle that underpins the conduct of science itself: successful innovation where financing, physical assets, knowledge and skills are combined from many sources to move new ideas quickly “from the bench to the bedside,” on behalf of patients everywhere.
A truly global program present in 14 countries*
Our program includes a review of contributions from a new generation of innovators representing diverse sectors in health. Our theme: better cross-cultural contacts, harmonized regulation, internal business process improvements, new information technologies and effective public-private partnerships can remove barriers to the commercialization of good medicines and expand access to these benefits to all who need them.
2018
Through our partnership with the Élie Wiesel Foundation for Humanity and our first initiative in Africa, 2018 will represent a new and exciting stage in the evolution of the Prix Galien as the pre-eminent “force populaire” behind the global scientific enterprise. With the support of our sponsoring organizations, our efforts will extend to all who see medical innovation not only as an industrial policy asset but as a source of social progress – where private enterprise and public engagement combine to deliver a greater public good.
We invite all communities with a commitment to the conduct and promotion of life sciences innovation to contribute to this important work.
* Belgium, Canada, China, France, Germany, Greece, Italy, Netherlands, Poland, Russia, Spain, Switzerland, United Kingdom and the United States.
Mission
3
The Prix Galien Award recognizes
outstanding achievements in improving
the global human condition through the
development of innovative drugs and
other treatments.
The Prix Galien was created in 1970 in
honor of Galen, the father of medical
science and modern pharmacology.
Worldwide the Prix Galien is regarded
as the equivalent of the Nobel Prize in
biopharmaceutical research.
innovation to improve
the human condition
4
2007-2011Committee
Paul GREENGARD, PhDNobel Laureate
Professor of Molecular and Cellular Neuroscience
Rockfeller University
Eric R. KANDEL, MDNobel Laureate
Professor of physiology and Cellular Biophysics
Columbia University
Paul A. MARKS, MDLaboratory Head of Cell Biology
Memorial Sloan KetteringCancer Center
Bengt SAMUELSSON, MD, PhDNobel Laureate
Professor Karolinska Institutet;Former President Karolinska Institutet; Former Chairman
Nobel Foundation
Jan T. VILCEK, M.D.Professor of MicrobiologyNew York University School
of Medicine
Gerald WEISSMANN, M.D.Professor of Rheumatology
and Director of Biotechnology Study Center
New York University School of Medicine
Elie WIESEL In Memoriam
Honorary Founding President
The Galien Foundation
Peace Nobel Laureate
Boston University
Michael S. BROWN, MDNobel Laureate
Professor of MolecularGenetics and Internal Medicine
UT SouthwesternMedical Center at Dallas
Barry S. COLLER, MDVice President for
Medical Affairsand Physician-in-Chief,Rockefeller University
Walter GILBERT, PhDNobel Laureate
Professor EmeritusHarvard University
Joseph GOLDSTEIN, MDNobel Laureate
Professor of MolecularGenetics and Internal Medicine
UT, SouthwesternMedical Center at Dallas
Joshua LEDERBERG, M.D. Ph.D.Nobel Laureate
Professor Emeritus, Laboratory of Molecular Genetics
and Informatics,Rockefeller University
Richard A. LERNER, M.D.Professor of Immunochemistry,
Chair in ChemistryScripps Research Institute
Richard AXEL, MD
Nobel Laureate
Co-director
The Kavli Institute for Brain
Science. Columbia University Medical Centre
Michael S. BROWN, MD
Nobel Laureate
Professor of Molecular Genetics
and Internal Medicine
UT Southwestern Medical
Center at Dallas
Laurie GLIMCHER, MD
President and CEODana Farber Cancer Institute;Professor of MedicineHarvard Medical School
Joseph GOLDSTEIN, MD
Nobel Laureate
Professor of Molecular Genetics
and Internal Medicine
UT, Southwestern Medical
Center at Dallas
Robert S. LANGER
David H. Koch Institute Professor
MIT
Cato T. LAURENCIN, MD, PhD
University Professor
University of Connecticut
Paul A. MARKS, MD
Laboratory Head of Cell Biology
Memorial Sloan Kettering
Cancer Center
Michael ROSENBLATT, MD
Chief Medical Officer
Flagship Pioneering at Dallas
Bengt SAMUELSSON, MD, PhD
Nobel Laureate
Professor
Karolinska Institutet;
Former President
Karolinska Institutet;
Former Chairman
Nobel Foundation
Marc TESSIER-LAVIGNE, PhD
President
Stanford University
P. Roy VAGELOS, MD
Prix Galien USA
Committee Chairman 2012-2017
Retired Chairman and CEO
Merck & Co., Inc.;
Chairman of the Board
Regeneron Pharmaceuticals, Inc.
5
Susan DESMOND-HELLMANN, MD, MPh
Committee Chair
Chief Executive Officer
Bill & Melinda Gates Foundation
AWARDS COMMITTEE
2018
Our 700 attendees represent the top executive and thought
leadership from academic research, industry, government, the
regulatory community, patient organizations, international
organizations, and the media. Time and again, Forum participants
praise the caliber of the speakers and their fellow attendees,
the quality of the panel discussions and presentations, and
the recognition of industry’s critical role in creating life-saving
innovations.
These events represent peer-to-peer exchange with a public
purpose, and they feature unique opportunities to connect with
a diverse range of people, organizations, and interests, from
professional and scientific groups, academia and governments to
patient associations, non-profit organizations and the media.
Visit the forum webcast to read our 2017 Forum Report on people and substance and to see videos and photos from the event
Topics debated at previous forums include:
> Cancer Immunotherapeutics
> The Brain Initiative
> Personalized Medicine’s Impact on Drug R&D and Patient Care
> Improving efficiency in Drug Development
> What is “Value” and How Can it be Measured and
Demonstrated in Therapeutic Innovations?
> U.S. Health Reform
> A New Agenda for Global Health
> The Future of Digital Health and its Impact on Healthcare
> New Mechanisms for Industry-Academia Collaboration
> The Future of Targeted Drug Delivery
> Microbiota in Human Disease
> Autism - The Next Decade
> Untangling the Web of Neurodegeneration
> Precision Medicine: Delivering on the Promise
> Molecular Scissors: What Can We Expect from Gene Editing?
The Galien Forum, held every autumn at New York’s Alexandria Center for
Life Sciences since 2010, offers a full day of dynamic presentations and
spirited discussions with top scientists and industry researchers who
offer perspectives on the most significant challenges in the global burden
of disease and highlight the latest research and clinical pathways toward
diagnosis, treatment, and cure.
Galien FORUM october 25, 2018 - 7:30AM ALEXANDRIA CENTER FOR LIFE SCIENCE
NEW YORK CITY
6
Margaret A. Hamburg, MDFormer CommissionerU.S. Food and Drug Administration
Sachin H. Jain, MD, MBAChief Medical informationand innovation officer Merck and Co.;Lecturer in Healthcare Policy Harvard Medical School
William N. Hait, MD, PhDGlobal Head, Researchand DevelopmentJanssen Research& Development
Paul Greengard, PhDNobel Laureate Professor of Molecular and Cellular Neuroscience Rockefeller University
Eric R. Kandel, MDNobel LaureateProfessor of Physiologyand Cellular BiophysicsColumbia University;Director Bio-technology Study Center, NYU School of Medicine
Bengt Samuelsson, MD, PhDNobel LaureateFormer PresidentKarolinska InstituteFormer ChairmanNobel Foundation
Michael Rosenblatt, MD Chief Medical Officer Flagship Ventures
Dr Morgan ShengVice PresidentNeuroscience Genentech
George A. Scangos, PhDChief Executive OfficerBiogen Idec
Guido RasiExecutive Director European MedicinesAgency
Laurie Glimcher, MDCEO and PresidentDana Farber Cancer Institute;Professor of MedicineHarvard Medical School
Ezekiel Emanuel, MD, PhDVice Provost for Global Initiatives; Chair,Dept. of Medical Ethicsand Health Policy Levy University Professor Perelman School of Medicine and The Wharton School, University of Pennsylvania
Joseph GoldsteinNobel LaureateProfessor of Molecular Genetics and Internal MedicineUT, Southwestern MedicalCenter at Dallas
Kenneth C. FrazierChaiman, CEO and President,Merck
Dr Alex GorskyChaiman and CEOJohnson & Johnson
Maria C. Freire, PhD President & Executive DirectorFoundation for the National Institutes of Health
Mark McClellan, MD, PhDDirectorDuke-Robert J. Margolis Center for Health Policy;Professor of Business, Medicine, and Health Policy Duke University
Joel S. MarcusChairman, CEO & FounderAlexandria Real Estate Equities /Alexandria Venture Investments; Co-FounderAlexandria Summit
Dr Ira MellmanVice PresidentResearch Genentech
Donald Lloyd-JonesChairman, Departmentof Preventive MedicineNorthwestern University
John LechleiterChairman and CEO Eli Lilly & Cie
Dr Jeffrey LeidenChairman, President and CEOVeritex
Tara Narula, MD, FACCMedical Contributor“CBS This Morning”
Steven H. Stein, MDSenior Vice PresidentUS Clinical Development& Medical AffairsNovartis Oncology US
Marc Tessier-Lavigne PhDPresidentStanford University
Elias ZerhouniPresident, Global R&DSanofi
Krishna Yeshwant, MDGeneral PartnerGoogle Ventures
George Yancopoulos, MD, PhDChief Scientific Officer Regeneron PharmaceuticalsPresident, Regeneron Laboratories
Bert VogelsteinProfessorJohns Hopkins Medical School
P. Roy VagelosM.D., Retired Chairman and CEO, Merck & Co., Inc.Chairman of the Board, Regeneron Pharmaceuticals
Mikael Dolsten, MD, PhDPresident, Worldwide Research and Development Pfizer
Richard Axel, MDNobel Laureate Co-directorKavli Institute for Brain Science, Columbia University Medical Centre
Cori Bargmann PhDRockefeller University
Michael S. BrownNobel LaureateProfessor of Molecular Genetics and Internal MedicineUT Southwestern MedicalCenter at Dallas
Rory CollinsCo-directorUniversity of OxfordClinical Trials Unit
Dr Samantha BuddVice PresidentNeuroscience iMed,AstraZeneca R&D
Michael BloombergFormer Mayor City of New York
AMONG
THE PREVIOUS
GALIEN
FORUM
SPEAKERS
7
“I’d also like to congratulate all thecandidates for the 5th Annual Prix Galien Awards Competition, which honors those
in the pharmaceutical industry who have developed the technical, scientific
and clinical research skills necessary to develop innovative medicines and
devices. Your work is invaluable.“
Margaret A. Hamburg, M.D.
Commissioner of Food and DrugsUS Food and Drug Administration - 2011
“We recognize the importance of the PrixGalien in promoting drug research, and
we salute the excellent work of the Jury.“
Philippe Douste-Blazy French Minister of Foreign Affairs – 2006
“When Olympic rhymes with Galenic: there is a gold medal that can be won
for an extraordinary achievement: this is the Galien Award, the Oscar of
pharmaceutical research.“
Walter SutterSwiss State Advisor, Director
of the Public Economy - 2004
“I applaud Prix Galien for recognizing the pioneering spirit of America
innovation and research.“
John McCain
American Senator - 2008
“Prix Galien recognizes men and women
from the pharmaceutical and biomedical
industries whose contributions of science
have improved and saved countless lives.“
Michael Bloomberg
Mayor of the City of New York - 2010
“The Prix Galien USA recognizes theimportant research necessary to develop innovative medicines and devices that have a life-saving impact on individuals
and families across the globe.“
Kathleen Sebelius
American Secretary of Health and Human Services - 2011
“The Galien Foundation, created to honor and catalyze excellence in scientific innovation, recognizes outstanding
achievement with the prestigious Prix Galien Award.“
Bill De BlasioMayor of the City of New York - 2015
8
A record of leadership in bringing the best of biomedical discovery to the attention of the world…
“
““The Prix Galien is a welcome
initiative to stimulate creative
research and promote excellence.“
Barack Obama
American President - 2008
“I am particularly grateful
to receive this Award.“
Bill Clinton
American President - 2010“The Prix Galien is a prestigious award,
a magnificent occasion to pay recognition to our researchers and
to encourage our industry.“
Jean ChretienCanadian Prime Minister - 1994
“I welcome you to the annual Prix Galien awards for innovative excellence
in biomedical products and health technologies. The awards are among
the highest honors in science and commerce..“
Jimmy Carter
American President - 2017
“It is a pleasure to congratulate all
those who promote the Prix Galien and
pharmaceutical research: they play a vital
role in the fight against disease throughout
the world.“
John Major
British Prime Minister - 1996
“The Prix Galien is the right event, on the
right issue at the right time. I thank the
Galien Foundation for bringing us together
and for recognizing that a healthier world is
a safer world and a more just world.“
BAN Ki-moon
UN Secretary-General - 2010
9
“I know the importance of the Prix Galien
which rewards every year therapeutic
innovations and research works among
the most creative.“
Emmanuel Macron
French President - 2018
“The Prix Galien since 1970 is dedicated
to promoting the research
and development of the medicine
and medicine industries.“
Macky Sall
Senegalese President - 2018
The Prix Galien medal was designed by Albert de Jaeger (1908 – 1992), laureate of
the Premier Grand Prix de Rome architectural prize. De Jaeger designed medals for
prominent figures such as Pope Pius XII (at the Villa Medicis, 1937) and Pope Jean-Paul I,
Presidents Dwight D. Eisenhower and John F. Kennedy, distinguished military leaders
including Marshals Leclerc, Koenig, Montgomery, Marshall and Joukov; the Weizmann
Institute, as well as numerous artists, literary figures and prominent personalities such as Sacha
Guitry, Marcel Proust, Henri de Montherlant, Paul Harris, a number of Nobel Prize laureates, the
Empress of Iran SA Farah Diba, Princess Grace of Monaco, and others…
De Jaeger is also the architect of numerous outstanding monuments in France and throughout the world.
Medalby Albert de JAEGER
The
Merck
Novartis
Roche
Sanofi
GlaxoSmithKline
J&J/Janssen
Pfizer
Bristol-Myers Squibb
Bayer
Amgen
Abbott, Servier
Boehringer Ingelheim
Astra-Zeneca, Inserm, Vertex
Gilead Sciences, Lilly
Biogen, Institut Pasteur, Takeda Actelion, Alexion, Almirall, Teva
AP-HP, Celgene, Chiesi, CTRS, Edwards Life-sciences, Fresenius Biotech, Genzyme, Institut Merieux, Ipsen, Lundbeck, Pierre-Fabre, Procter & Gamble, PTC Thera-peutics, Shire Pharmaceuticals AAZ, AbbVie, Abbott/AbbVie, Albana Pharma, Army Health Department - France, Astellas, Baxter, Biocodex, Boston Scientific, Centre of Polymer and Carbon Materi-als of the Polish Academy of Sciences, Chugaî, Engel-hardt Institute of Molecular Biology, EOS Imaging, Ferrer, Genethon, Genentech, Generium, Guerbet, Institut Santa Creu, Intercept Pharmaceuticals, Insightec, Intermunde, Ionis Pharmaceuticals, Leo, LFB, Menarini, Norgine GmbH, Orphan, Otzuka, PharmaPharm, Roche/Genen-tech, Swedish Orphan International, T2 Biosystems, Uriach, Viron Therapeutics,
B Y N U M B E R O F M E D A L S
Hall of famePRIX GALIEN
Around the globe since 1970
51
45
6
42
5
37
4
35
3
32
2
1
28
23
17
16
Updated December 2017
11
8
10
1 1
Our annual gala awards dinner is a creative
recognition of the productive and positive power
of partnerships that drive progress in medical
science. It is peer exchange with a public purpose
- with a diverse range of opportunities for contact
with a range of interests, from professional and
scientific groups, academia and governments
to patient associations, other non-profit
organizations and the media.
october 25, 20186:30 PM
Galien AWARDS CEREMONY
AMERICAN MUSEUM OF NATURAL HISTORY
NEW YORK CITY
WHAT PREVIOUS PRIX GALIEN WINNERS HAVE SAID UPON RECEIVING THE HONOUR
“Merck’s mission is to
translate science into
medically important
products that positively
impact humanity, so it is
natural for us to support the Prix
Galien, since it supports exactly that.”
Kenneth C. Frazier
Chaiman, CEO and President
Merck
2018
“Our 2016 Prix Galien award
highlights not only the
breakthrough science behind
Cologuard, but also the
unrivaled team that worked to
develop and bring to market an innovation
with the potential to make a significant
impact in eradicating colorectal cancer. We
are humbled and thankful to be counted
among the companies honored by the
Galien Foundation.”
Graham Lidgard, PhD
Chief Science Officer
Exact Sciences
“Our goal — to combine the
best science with the most
efficient drug development
plan and deliver
transformational medicines to
patients in need — is completely aligned
with the Galien Foundation mission to
promote innovations that improve the
human condition.”
Mace L. Rothenberg,
M.D. Chief Development Officer, Oncology -
Pfizer Global Product Development
“The Galien Foundation
brings together the top
scientists in the world.
You have Nobel Laureates
across the spectrum of
scientific disciplines meeting and
talking with members of the pharmaceutical
industry to see what’s going on at the
cutting edge, because ultimately that’s
going to benefit patients.”
William Hait, MD, PhD
Global Head, Research & Development
Janssen, Pharmaceutical Companies of
Johnson & Johnson
“Our 2016 Prix Galien USA
awards [for Cosentyx and
Gleevec] … represent years
of hard work by our scientists.
These wins underscore our
commitment to addressing the
unmet medical needs of patients through
science-based innovation.”
Joseph Jimenez
CEO
Novartis
The committee follows a century-old example set in Sweden.
The Prix Galien rewards excellence and novelty, and awards special honors to
those who have served humanity at large. Presented at the Ceremony, the Pro
Bono Humanum Award recognizes exemplary and innovative efforts in improving
the human condition. This special award was presented by the late and beloved
Elie Wiesel, in presence of the Prix Galien USA Committee.
2011Pr. Paul Farmer in recognition of his heroic efforts to do “whatever it takes” to improve the lives and health of patients in destitute communities around the world through the Partners in Health initiative which he co-founded with Tom White.
2010Bill Clinton and Philippe Douste-Blazy, in recognition of their outstanding achievements in providing treatment for underserved populations through the William J. Clinton Foundation HIV / AIDS Initiative and the multilateral organization, UNITAID.
2009Harvard Professor Barry Bloom for bringing the fruits of basic biological science to those who are most needy. Columbia University Earth Institute Director Jeffrey Sachs for bringing the fruits of scholarly economics to bear our problems that have plagued the world for millennia.
2008Sheldon Segal and the Population Council for their global efforts in support of reproductive health and family planning.
2007Former Merck CEO Roy Vagelos, for the River Blindness Program and his historic decision to donate the drug Mectizan® to more than 530 million people in 34 countries to treat and prevent river blindness: “as much as necessary for as long as necessary.”
2017President Jimmy Carter & The Carter CenterIn recognition of his role as the nation’s 39th President in expanding access to childhood immunizations and, for the first time, adding social progress and human rights as a foundational principle of US foreign policy. The Prix Galien USA Committee also commends his unmatched record in public health provision after leaving office, launching the Carter Center in 1982 and subsequently positioning it as a leading global donor on programs to control and eradicate six major communicable diseases prevalent in developing
countries. This includes the eradication of the Guinea worm disease as well as the MECTIZAN initiative to control the scourge of river blindness in Africa and Latin America, which today serves as a precedent for productive public-private partnerships. The Committee points as well to his selection as recipient of the Nobel Peace Prize in 2002, in which the Swedish Academy noted his decades of effort to promote individual freedoms and economic and social development for all. These are now recognized around the world as important drivers of individual health status.
2016Paula S. Apsell
In recognition of her early and
continuing leadership in Making the
complexities of science, engineering
and medical research accessible to a
mass audience. Through innovative
broadcast and digital programming
of the highest journalistic
standard, her work has educated,
entertained and enlightened
successive generations of viewers
on the mysteries that underlie our
understanding of the natural world.
And by turning great science into
a good story - a human story - Ms.
Apsell shows that scientific literacy
is society’s essential line of defense
against the destructive forces of fear,
ignorance and blight.
2015Pr. Mary-Claire King
In recognition of your
work in transforming the
application of human
genetics to medicine through
identification of
the first gene, BRCA1,
responsible for inherited
susceptibility to breast
cancer. You also
demonstrated that the
genomes of humans and
chimpanzees are 99%
identical, and you pioneered
the application of genetic
sequencing in forensics to
identify victims of human
rights abuse.
2014Bernard Kouchner, M.D.
In recognition of his role in
the creation, from amongst
French doctors, this group of
“Doctors Without Borders”
who have lent the modern
field of humanitarian
medicine both legitimacy
and worldwide acclaim and
for his fieldwork that has
nurtured and developed,
not only among public
opinion but also within
various governments, the
notion of the universality
of humanitarian action and
the concept of the Non-
Governmental Organization.
2013Dr. Anthony Fauci
for his paramount
contributions to basic and
clinical research on the
pathogenesis and treatment
of immunemediated and
infectious diseases.
He currently serves as
Director of the NIAID and
chief of the NIAID Laboratory
of Immunoregulation in
Bethesda, Maryland.
2012Dr. Francis S. Collins.
Dr. Collins, Director of the
National Institutes of Health
(N.I.H)
In recognition of his
contribution to the ethical
implications of scientific
research
12
The Prix Galien USA Committee, a group of highly accomplished individuals from the scientific and research communities,
will judge which among the candidates, independent of any category, is the Best Pharmaceutical Agent (i.e. small molecule),
is the Best Biotechnology Product and which is the Best Medical Technology approved by the FDA in the past ten years. As
few as one or as many as three prizes may be awarded in each of these categories, and from time to time the committee
may decide on awards hors prix. The prizes are awarded for products and agents that improve the human condition.
An UNRIVALED REPUTATION FOR INTELLECTUAL RIGOR AND INTEGRITY…
Elie Wiesel, Peace Nobel Laureate;
BAN Ki-moon, General Secretary, United Nations;
Bill Clinton & Philippe Douste-Blazy,
2010 Prix Galien Pro Bono Humanum Award Laureate
Born in 131AD, Galen (Galien in French) is
considered the father of modern medicine
and pharmacology.As an anatomist,
physiologist, clinician and researcher,
his work formed the basis of a school
of thought known as “Galenism”, which
dominated medicine until the Renaissance.
In fact, Galen’s works were used as primary
medical reference for nearly two centuries.
Raised in Pergamos, he studied in Smyrna,
Corinth, and Alexandria, the three centers
of medical excellence in the ancient world.
Legend has it that Galen was visited
by Aesclapius in a dream and that this
inspired the direction of his life. When he
was 17, Galen worked as a physician to
the gladiatorial school. At the age of 37,
Marcus Aurelius summoned him to Rome,
where he grew in reputation and stature
as a healer, teacher, researcher and writer.
His ideas on the functioning of the human
body were so well received that he became
the personal doctor of young Commodus,
the heir to the Emperor. He died in 201AD.
During his long and eminent career, Galen
completed over five hundred learned works
addressing anatomy, physiology, pathology,
medical theory and practice, and many
forms of therapy. He traveled throughout the
world, studying local plants and remedies,
eventually describing 473 original drugs and
many substances of mineral and vegetable
origin. Importantly, Galen was the first to
codify the art of preparing active drugs
using multiple ingredients. Galen’s faculties
of observation, logic and deduction made
him the true successor of Hippocrates,
and his declaration that the primary aim of
medicine was patient care formed the very
cornerstone of modern pharmacy.To quote
Jean-Pierre Changeux, “Galen first showed
that our mind was in the brain, not in our
hearts.” It can be said that this was the
beginning of experimental medicine.
Who was Galien?
13
The mission of The Prix Galien-MedStartUp program is to foster
private-sector collaborations to treat and cure medical conditions
that pose a threat to public health worldwide and promotes
foster innovative research partnerships among major integrated
pharmaceutical companies, biotech firms, and medical device
manufacturers, producers of vaccines, academic research institutes,
and health care organizations, including e-health vendors.
This unique initiative, which takes place in
the same venue and at the same time as the
Galien Forum, was built on several years of
cooperation between the Galien Foundation and
Business France with three core goals:
Strengthen commercial partnerships
that bridge the traditional silos between
government, industry and academia;
Defray the growing complexity and cost
burden of medicines R&D; and
Promote cross-border trade, jobs, and
economic growth.
A focal point of the program is the active
participation of the most innovative start-up
companies who are seeking US partners to
share research and support global commercial
development of promising lead technologies.
Each year the Jury nominates candidates
for four awards in the following categories:
Best Collaboration/Partnership with an
Academic institution in a Breakthrough
Therapy
Best Innovative Clinical Trial Design to achieve
a Faster and Better Therapeutic Outcome
Best Use of a Patient-Centered Health
Engagement Technology
Best Collaboration/Partnership in a
Breakthrough Therapy or Diagnosis
geared to Developing Countries.
14
THE JURY
JOIN US ON : http://medstartup.galienfoundation.org +
François MAISONROUGESenior Managing Director,Evercore Partners
Paul STOFFELSChief Scientific Officer, Johnson and Johnson
Elias ZERHOUNIGlobal R&D President, Sanofi
!
!
!
Roch DOLIVEUXHonorary CEO, UCB
Mikael DOLSTENGlobal R&D President, Pfizer
Jean-Pierre GARNIERFormer CEO, GSK
Franz HUMERFormer CEO, Roche
!
!
!
!
!
Chairman:
Bernard POUSSOT
Director, Roche Holding, Former Chairman & CEO, WYETH
15
2017Best Pharmaceutical Product: Venclexta™, AbbVie & Genentech (a Member of the Roche Group)
Best Biotechnology Product: SPINRAZA®, Biogen & Ionis Pharmaceuticals
Best Medical Technology: Exablate Neuro, INSIGHTEC
Pro Bono Humanum Award:Former President Jimmy Carter
2016Best Pharmaceutical Agent: Ibrance®, Pfizer, Inc.
Best Biotechnology Product: Cosentyx®, Novartis Pharma.
Best Medical Technology: Cologuard®, Exact Sciences
Discovery of the Decade winners:
Best Pharmaceutical Agent: Gleevec®, Novartis Pharma.
Best Biotechnology Product: Yervoy®, Bristol-Myers Squibb
Best Medical Technology: Sapien 3TM, Edwards Lifesciences Corpo.
Pro Bono Humanum Award: Paula S. Apsell
2015Best Pharmaceutical Agent: IMBRUVICA®, Janssen Biotech, Inc. & Pharmacyclics LLC, an AbbVie Company
Best Biotechnology Product: OPDIVO®, Bristol-Myers Squibb KEYTRUDA®, Merck & Co., Inc.
Best Medical Technology: T2Candida Panel, T2 Biosystems, Inc.
Pro Bono Humanum Award:Pr. Mary-Claire King
2014Best Pharmaceutical Agent: Sovaldi® - Gilead Sciences
Best Biotechnology Product: HEMACORD® - The New York Blood Center’s Howard P. Milstein Cord Blood Center
Best Medical Technology: Trevo ProVue® - Stryker
Pro Bono Humanum Award:Dr. Bernard Kouchner
2013Best Pharmaceutical Agents:Zelboraf® - Genentech
Best Biotechnology Product:Zostavax® - Merck
Best Medical Technology product:S-ICD® System - Boston Scientific
Pro Bono Humanum Award:Dr. Anthony S. Fauci
2012Best Pharmaceutical Agents:Victrelis® - Merck; Incivek® - Vertex
Best Biotechnology Product:Yervoy® - Bristol-Myers Squibb
Best Medical Technology product: Sapien® - Edwards Lifesciences’Melody® - Medtronic
Pro Bono Humanum Award:Dr. Francis S. Collins
2011Best Pharmaceutical Agent:Prevnar13® - Pfizer
Best Biotechnology Product:Stelara® - Janssen Prolia and XGEVA® - Amgen
Pro Bono Humanum Award:Paul Farmer
2010Best Pharmaceutical Agent:Coartem® - Novartis
Best Biotechnology Product:RotaTeq® - Merck & Co.
Best Medical Technology:xTAG® - Luminex Corporation
Pro Bono Humanum Award:Bill Clinton and Philippe Douste-Blazy
2009Best Pharmaceutical Agent:Gleevec® - Novartis
Best Biotechnology Product:Nplate® - Amgen; Promacta® - GSK
Best Medical Technology:Cellsearch® - Veridex (J&J)
Pro Bono Humanum Award:Jeffrey Sachs and Barry Bloom
2008Best Pharmaceutical Agent:Isentress® - Merck; Selzentry® - Pfizer
Best Biotechnology Product:Soliris® - Alexion; Infuse® - Wyeth
Special therapeutic development:Revlimid® - Celgene
Pro Bono Humanum Award:
Sheldon Segal
2007Best Pharmaceutical Agent:Januvia® - Merck; Chantix® - Pfizer
Best Biotechnology Product:Humira® - Abbott; Gardasil® - Merck
Pro Bono Humanum Award:Dr. Roy Vagelos
And in 2018, the winners are…PRIX GALIEN USA WINNERS
The Galien Foundation
99 John Street , Suite 2502.
New York, New York 10038
212-685-1592
and the winner is…
Actors win Oscars. . .
Innovators win Prix Galien USA
The Galien Foundation
99 John Street, Suite 2502
New York, NY 10038
Tel: 212-685-1592
Prevnar13® / Prolia and XGEVA® / Stelara®
Coartem® / Rotateq® / xTAG®
HemacordTM / Trevo®ProVueTM
Sovaldi®
S-ICD® SystemZelboraf® / Zostavax®
Imbruvica®/ Keytruda®/ Opdivo® / T2Candida Panel
Cologuard® / Cosentyx® Ibrance®
2016 2016
2015 2015
2014 2014
2013 2013
2011 2011
2010 2010
Cellsearch® / Gleevec® / Nplate® / Promacta®2009 2009
Infuse® / Isentress® / Revlimid®/ Selzentry® / Soliris®2008 2008
Chantix® / Gardasil® / Humira® / Januvia® 2007 2007
www.galienfoundation.org
OCTOBER 25, 2018
AMERICAN MUSEUM OF NATURAL HISTORY
Exablate Neuro®
Spinraza® / VenclextaTM 2017 2017
Incivek® / Melody® / Sapien®
Victrelis® / Yervoy®2012 2012